<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="575">
  <stage>Registered</stage>
  <submitdate>26/05/2005</submitdate>
  <approvaldate>26/05/2005</approvaldate>
  <nctid>NCT00111852</nctid>
  <trial_identification>
    <studytitle>Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS-2)</studytitle>
    <scientifictitle>A Prospective, Randomized, Double-blind, Placebo-controlled, Single Bolus, Multinational, Multi-center, Parallel Group, Dose-ranging Study of Desmoteplase (INN) in the Indication of Acute Stroke</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>DSP-MD-01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Stroke, Acute</healthcondition>
    <conditioncode>
      <conditioncode1>Stroke</conditioncode1>
      <conditioncode2>Haemorrhagic</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Stroke</conditioncode1>
      <conditioncode2>Ischaemic</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Desmoteplase
Treatment: drugs - Desmoteplase
Treatment: drugs - Placebo

Experimental: Desmoteplase, low dose - Desmoteplase 90 mcg/kg, intravenous administration.

Experimental: Desmoteplase, high dose - Desmoteplase 125 mcg/kg, intravenous administration.

Placebo Comparator: Placebo - Dose-Match Placebo, intravenous administration.


Treatment: drugs: Desmoteplase
Desmoteplase 90 mcg/kg, intravenous administration.

Treatment: drugs: Desmoteplase
Desmoteplase 125 mcg/kg, intravenous administration.

Treatment: drugs: Placebo
Dose-Match Placebo, intravenous administration.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>National Institutes of Health Stroke Scale (NIHSS) - Improvement of greater than or equal to 8 points from baseline, or NIHSS score less than or equal to 1. The NIHSS score ranges from 0 (least severe) to 42 (more severe).</outcome>
      <timepoint>Change from Baseline to day 90</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Modified Rankin Scale (MRS) - Improvement on the Modified Rankin Scale, defined as a score of 0-2. The MRS ranges in severity from 0 (no symptoms) to 6 (Dead).</outcome>
      <timepoint>Day 90</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Barthel Index (BI) score of 75-100. - The Barthel Index (BI) is a scale used to measure performance in basic Activities of Daily Livingranges from 0 (most disablility) to 100 (no disability)</outcome>
      <timepoint>Day 90</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of patients with improvement in NIHSS score - Improvement of greater than or equal to 8 points from baseline on the NIHSS score, or NIHSS score less than or equal to 1.</outcome>
      <timepoint>From Baseline to Day 90</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of patients with MRS score of 0-2</outcome>
      <timepoint>Day 90</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of patients with BI score of 75-100</outcome>
      <timepoint>Day 90</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Infarct Volume</outcome>
      <timepoint>Change from baseline to Day 30</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Eligible for study treatment within 3-9 hours after onset of stroke symptoms.

          -  Score of 4-24 on the NIHSS with clinical signs of hemispheric infarction (i.e.
             hemiparesis) suggestive of ischemic stroke.

        Inclusion Criteria from diagnostic imaging screening:

          -  Distinct penumbra (at least 20%), measured by MRI (PWI/DWI) or perfusion CT, related
             to middle cerebral artery (MCA), anterior cerebral artery (ACA), or posterior cerebral
             artery (PCA) territory in a hemispheric distribution.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History or clinical presentation of intracranial hemorrhage (ICH), subarachnoid
             hemorrhage, arteriovenous malformation, aneurysm, or cerebral neoplasm.

          -  Rapidly improving neurological symptoms.

          -  Pre-stroke MRS score of &gt; 1 (including previous disability).

          -  Suspected acute vertebral or basilar artery occlusion.

          -  Current use of anticoagulants and a prolonged prothrombin time.

          -  Uncontrolled hypertension.

          -  Baseline hematocrit of &lt; 0.25.

          -  Baseline platelet count &lt; 100,000/mm3.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>193</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>John Hunter Hospital - New Lambton Heights</hospital>
    <hospital>Box Hill Hospital - Victoria</hospital>
    <hospital>Queen Elizabeth Hospital - Woodville</hospital>
    <postcode>NSW 2310 - New Lambton Heights</postcode>
    <postcode>3128 - Victoria</postcode>
    <postcode>SA 5011 - Woodville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Graz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Innsbruck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Linz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Kuopio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Badalona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Girona</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Forest Laboratories</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate desmoteplase (which is a manufactured protein
      derived from the saliva of the vampire bat) in dissolving clots that are blocking the flow of
      blood through one (or more) of the blood vessels supplying the brain, thereby reopening the
      blocked blood vessel and allowing blood to flow again in individuals suffering from ischemic
      stroke.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00111852</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Leslie Lipka, MD</name>
      <address>Forest Laboratories</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>